Tedizolid: A new oxazolidinone antimicrobial

American Journal of Health-System Pharmacy

Volumn 71, Issue 8, 2014, Pages 621-633

  Kisgen, Jamie J ^a   Mansour, Hanine ^b   Unger, Nathan R ^c   Childs, Lindsey M ^d  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b LEBANESE AMERICAN UNIVERSITY   (Lebanon)

^c NOVA SOUTHEASTERN UNIVERSITY   (United States)

^d DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LINEZOLID; MONOAMINE OXIDASE INHIBITOR; RNA 23S; SEROTONIN AGONIST; SEROTONIN UPTAKE INHIBITOR; TEDIZOLID; ACETAMIDE DERIVATIVE; ANTIINFECTIVE AGENT; OXAZOLIDINONE DERIVATIVE; TETRAZOLE DERIVATIVE;

ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; BACTEREMIA; BACTERIAL SKIN DISEASE; BACTEROIDES FRAGILIS; CLINICAL STUDY; CLOSTRIDIUM PERFRINGENS; COMMUNITY ACQUIRED PNEUMONIA; CORYNEBACTERIUM JEIKEIUM; DIARRHEA; DRUG BINDING; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DYSPEPSIA; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; GRAM POSITIVE INFECTION; HAEMOPHILUS INFLUENZAE; HEADACHE; HUMAN; IN VITRO STUDY; LISTERIA MONOCYTOGENES; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORAXELLA CATARRHALIS; NAUSEA; NEUROLOGIC DISEASE; PEPTOSTREPTOCOCCUS; PHASE 3 CLINICAL TRIAL (TOPIC); PREVOTELLA; PROTEIN SYNTHESIS; REVIEW; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; VANCOMYCIN RESISTANT ENTEROCOCCUS; VENTILATOR ASSOCIATED PNEUMONIA; VOLUME OF DISTRIBUTION; VOMITING; ANIMAL; COMPARATIVE STUDY; DRUG EFFECTS; DRUG INTERACTION; GRAM POSITIVE BACTERIUM; GRAM-POSITIVE BACTERIAL INFECTIONS; MICROBIOLOGY; MULTIDRUG RESISTANCE;

ACETAMIDES; ANIMALS; ANTI-BACTERIAL AGENTS; DRUG INTERACTIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; OXAZOLIDINONES; TETRAZOLES;

EID: 84907189741     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp130482     Document Type: Review

References (67)

1. Klein E, Smith DL, Laxminarayan R. Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999-2005. Emerg Infect Dis. 2007; 13:1840-6.
2. Klevens RM, Morrison MA, Nadle J et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA. 2007; 298:1763-71.
3. Kallen AJ, Mu Y, Bulens S et al. Health care-associated invasive MRSA infections, 2005-2008. JAMA. 2010; 304:641-7.
4. Tenover FC, Moellering RC Jr. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin Infect Dis. 2007; 44:1208-15.
5. Soriano A, Marco F, Martínez JA et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis. 2008; 46:193-200.
6. Musta AC, Riederer K, Shemes S et al. Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11 years. J Clin Microbiol. 2009; 47:1640-4.
7. Van Hal SJ, Lodise TI, Paterson DL. The clinical significance of vancomycin minimum inhibitory concentrations in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin Infect Dis. 2012; 54:755-71.
8. Murray BE. Vancomycin-resistant enterococcal infections. N Engl J Med. 2000; 342:710-21.
9. Ramsey AM, Zilberberg MD. Secular trends of hospitalization with vancomycin ?resistant enterococcus infection in the United States, 2000-2006. Infect Control Hosp Epidemiol. 2009; 30:184-6.
10. Cetinkaya Y, Falk P, Mayhall CG. Vancomycin-resistant enterococci. Clin Microb Rev. 2000; 13:686-707.
11. Zyvox (linezolid) package insert. New York: Pharmacia & Upjohn; 2013 May.
12. Paladino JA. Linezolid: an oxazolidinone antimicrobial agent. Am J Health-Syst Pharm. 2002; 59:2413-25.
13. Tsiodras S, Gold HS, Sakoulas G et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet. 2001; 358: 207-8.
14. Gonzales RD, Schreckenberger PC, Graham MB et al. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet. 2001; 357:1179.
15. Sá nchez García M, De la Torre MA, Morales G et al. Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit. JAMA. 2010; 303:2260-4.
16. Cubist Pharmaceuticals, Inc. Cubist announces submission of new drug application for investigational antibiotic tedizolid for treatment of serious skin infections. http://investors.cubist.com/file.aspx?IID=4093793&FID=20265968 (accessed 2013 Oct 25).
17. United States Adopted Names Council. Tedizolid. www.ama-assn.org/resources/doc/usan/tedizolid.pdf (accessed 2013 Jun 29).
18. Bozdogan B, Appelbaum PC. Oxazolidinones: activity, mode of action, and mechanism of resistance. Int J Antimicrob Agents. 2004; 23:113-9.
19. Locke JB, Finn J, Hilgers M et al. Structure-activity relationships of diverse oxazolidinones for linezolid-resistant Staphylococcus aureus strains possessing the cfr methyltransferase gene or ribosomal mutations. Antimicrob Agents Chemother. 2010; 54:5337-43.
20. Schaadt R, Sweeney D, Sinabarger D et al. In vitro activity of TR-700, the active ingredient of the antibacterial prodrug TR-701, a novel oxazolidinone antibacterial agent. Antimicrob Agents Chemother. 2009; 53:3236-9.
21. Brown SD, Traczewski MM. Comparative in vitro antimicrobial activities of torezolid (TR-700), the active moiety of a new oxazolidinone, torezolid phosphate (TR-701), determination of tentative disk diffusion interpretive criteria, and quality control ranges. Antimicrob Agents Chemother. 2010; 54:2063-9.
22. Lepak AJ, Marchillo K, Pichereau S et al. Comparative pharmacodynamics of the new oxazolidinone tedizolid phosphate and linezolid in a neutropenic murine Staphylococcus aureus pneumonia model. Antimicrob Agents Chemother. 2012; 56:5916-22.
23. Keel RA, Tessier PR, Nicolau DP. Comparative efficacies of human simulated exposures of tedizolid and linezolid against Staphylococcus aureus in the murine thigh infection model. Antimicrob Agents Chemother. 2012; 56:4403-7.
24. Livermore DM, Mushtaq S, Warner M et al. Activity of oxazolidinone TR-700 against linezolid-susceptible and -resistant staphylococci and enterococci. J Antimicrob Chemother. 2009; 63:713-5.
25. Rodriguez-Avial I, Culebras E, Betriu C et al. In vitro activity of tedizolid (TR-700) against linezolid-resistant staphylococci. J Antimicrob Chemother. 2012; 67:167-9.
26. Shaw KJ, Poppe S, Schaadt R et al. In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strains. Antimicrob Agents Chemother. 2008; 52:4442-7.
27. Jones RN, Moet GJ, Sader HS et al. TR-700 in vitro activity against and resistant mutation frequencies among gram-positive pathogens. J Antimicrob Chemother. 2009; 63:716-20.
28. Prokocimer P, Bien P, DeAnda C et al. In vitro activity and microbiological efficacy of tedizolid (TR-700) against gram-positive clinical isolates from a phase 2 study of oral tedizolid phosphate (TR-701) in patients with complicated skin and skin structure infections. Antimicrob Agents Chemother. 2012; 56:4608-13.
29. Choi S, Im W, Bartizal K. Activity of tedizolid phosphate (TR-701) in murine models of infection with penicillin-resistant and penicillin-sensitive Streptococcus pneumoniae. Antimicrob Agents Chemother. 2012; 56:4713-7.
30. Vera-Cabrera L, Gonzalez E, Rendon A et al. In vitro activities of DA-7157 and DA-7218 against Mycobacterium tuberculosis and Nocardia brasiliensis. Antimicrob Agents Chemother. 2006; 50:3170-2.
31. Cynamon MH, Sklaney M. In vitro activities of tedizolid compared to linezolid against Mycobacterium fortuitum. Paper presented at 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA; 2012.
32. Meka VG, Gold HS. Antimicrobial resistance to linezolid. Clin Infect Dis. 2004; 39:1010-5.
33. Mendes RE, Deshpande LM, Castanheira M et al. First report of cfr-mediated resistance to linezolid in human staphylococcal clinical isolates recovered in the United States. Antimicrob Agents Chemother. 2008; 52:2244-6.
34. Feng J, Lupien A, Gingras H et al. Genome sequencing of linezolid-resistant Streptococcus pneumoniae mutants reveals novel mechanism of resistance. Genome Res. 2009; 19:1214-23.
35. Locke JB, Hilgers M, Shaw KJ. Novel ribosomal mutations in Staphylococcus aureus strains identified through selection with the oxazolidinones linezolid and torezolid (TR-700). Antimicrob Agents Chemother. 2009; 53:5265-74.
36. Louie A, Liu W, Kulawy R et al. In vivo pharmacodynamics of torezolid phosphate (TR-701), a new oxazolidinone antibiotic, against methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains in a mouse thigh infection model. Antimicrob Agents Chemother. 2011; 55:3453-60.
37. Flanagan SD, Bien PA, Munoz KA et al. Pharmacokinetics of tedizolid following oral administration: single and multiple dose, effect of food, and comparison of two solid forms of the prodrug. Pharmacotherapy. Epub ahead of print. 2013 Aug 7.
38. Bien P, Prokocimer P, Muñoz K et al. Absolute bioavailability of TR-701 FA and pharmacokinetics after single and multiple dose intravenous administration in healthy adult subjects. Paper presented at 50th Interscience Conference Antimicrobial Agents and Chemotherapy. Boston, MA; 2010.
39. Sahre M, Sabarinath S, Grant M et al. Skin and soft tissue concentrations of tedizolid (formerly torezolid), a novel oxazolidinone, following a single oral dose in healthy volunteers. Int J Antimicrob Agents. 2012; 40:51-4.
40. Housman ST, Pope JS, Russomanno J et al. Pulmonary disposition of tedizolid following administration of once-daily oral 200-milligram tedizolid phosphate in healthy adult volunteers. Antimicrob Agents Chemother. 2012; 56:2627-34.
41. Dreskin H, Boyea T, Barker J et al. An evaluation of the absorption, metabolism, and excretion of orally administered [14C]-TR-701 FA in healthy subjects. Paper presented at 51st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL; 2011.
42. Drusano GL, Liu W, Kulawy R et al. Impact of granulocytes on the antimicrobial effect of tedizolid in a mouse thigh infection model. Antimicrob Agents Chemother. 2011; 55:5300-5.
43. Mondick J, Gastonguay MR, Bien P et al. Population pharmacokinetic modeling of TR-700 in patients with complicated skin and skin structure infections. Poster presented at 50th Interscience Conference on Antimicrobial Agents and Chemotherapy. Boston, MA; 2010.
44. Prokocimer P, Bien P, Surber J et al. Phase 2, randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections. Antimicrob Agents Chemother. 2011; 55:583-92.
45. Dreskin H, Muñoz KA, Fang E et al. Safety and pharmacokinetics of single oral administration of tedizolid phosphate in healthy elderly subjects and adult control subjects. Poster presented at 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA; 2012.
46. Dreskin H, Muñoz KA, Bradley J et al. Safety and pharmacokinetics after single oral and IV administration of tedizolid phosphate in adolescent patients. Poster presented at 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA; 2012.
47. Flanagan S, Morris D, Boyea T et al. A phase 1 study of intravenously administered tedizolid phosphate in subjects with advanced renal impairment. Poster presented at 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA; 2012.
48. Flanagan S, Boyea T, Dreskin H et al. A phase 1 study of orally administered tedizolid phosphate in subjects with moderate or severe hepatic impairment. Poster presented at 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA; 2012.
49. Andes D, van Ogtrop ML, Peng J, Craig WA. In vivo pharmacodynamics of a new oxazolidinone (linezolid). Antimicrob Agents Chemother. 2002; 46:3484-9.
50. Chan L, Basuino L, Chambers H. Efficacy of tedizolid phosphate in a rabbit model of methicillin-resistant Staphylococcus aureus endocarditis. Paper presented at 2nd annual IDWeek. San Francisco, CA; 2013.
51. Xiong Y, Abdel Hady W, Bartizal W, Bayer A. Comparative efficacy of tedizolid (TZD), linezolid (LZD) and vancomycin (VAN) in a murine model of catheterrelated biofilm infection due to Staphylococcus aureus (SA): microbiological and bioluminescent assessments. Poster presented at 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Denver, CO; 2013.
52. Bien P, Prokocimer P, Munoz KA, Bohn J. Safety of multiple ascending oral doses of the prodrug TR-701, a novel oxazolidinone antibiotic. Abstract (P1089) presented at 19th European Congress of Clinical Microbiology and Infectious Diseases. Helsinki, Finland; 2009 May.
53. Prokocimer P, De Anda C, Fang E et al. Tedizolid phosphate vs. linezolid for the treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial. JAMA. 2013; 309:559-69.
54. Fang E, De Anda C, Das A et al. Efficacy and safety results from the ESTABLISH-2 ABSSSI study comparing IV and oral tedizolid phosphate and linezolid. Paper presented at 23rd European Congress of Clinical Microbiology and Infectious Diseases. Berlin, Germany; 2013 Apr 28.
55. Kanafani Z, Corey R. Tedizolid (TR-701): a new oxazolidinone with enhanced potency. Expert Opin Investig Drugs. 2012; 21:515-22.
56. Prokocimer P, Bien P, Munoz KA et al. Hematological effects of TR-701, linezolid and placebo administered for 21 days in healthy subjects. Presentation at 48th Interscience Conference on Antimicrobial Agents and Chemotherapy/46th Meeting of the Infectious Diseases Society of America. Washington, DC; 2008.
57. Doron S, Boucher HW. Antibiotics for skin infections. New study design and a step toward shorter course therapy. JAMA. 2013; 309:609-11.
58. Fang E, Litwin J, Lewis W et al. Effects of oral tedizolid phosphate on QTcF and other electrocardiogram parameters. Presentation at 23rd European Congress of Clinical Microbiology and Infectious Diseases. Berlin, Germany; 2013.
59. Flanagan S, Bartizal K, Minassian SL et al. Tedizolid in vitro, in vivo, and clinical studies to assess the potential for peripheral or central monoamine oxidase interactions. Antimicrob Agents Chemother. 2013; 57:3060-6.
60. Stahl SM, Felker A. Monoamine oxidase inhibitors: a modern guide to an unrequited class of antidepressants CNS Spectr. 2008; 13:855-70.
61. Mangili A, Bica I, Snydman DR et al. Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis. 2005; 40:1058-60.
62. Werner G, Gfrörer S, Fleige C et al. Tigecycline-resistant Enterococcus faecalis strain isolated from a German intensive care unit patient. J Antimicrob Chemother. 2008; 61:1182-3.
63. Spellberg B, Guidos R, Gilbert D et al. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin Infect Dis. 2008; 46:155-64.
64. Boucher HW, Talbot GH, Bradley JS et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis. 2009; 48:1-12.
65. Infectious Diseases Society of America. The 10 x 20 initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin Infect Dis. 2010; 50:1081-3.
66. World Health Organization. The evolving threat of antimicrobial resistance - options for action: 2012. http://whqlibdoc.who.int/publications/2012/9789241503181-eng.pdf (accessed 2013 Jun 29).
67. ClinicalTrials.gov. A phase III study to evaluate the efficacy and safety of BAY 1192631 in Japanese patients with MRSA infections (SSTI and SSTI-related bacteremia). http://clinicaltrials.gov/ct2/show/NCT01967225?term=tedizolid&rank=3 (accessed 2014 Jan 23).